

*Drug Therapy*ALASTAIR J.J. WOOD, M.D., *Editor***HEMOSTATIC DRUGS**

PIER MANNUCCIO MANNUCCI, M.D.

**W**HEN bleeding is the consequence of a specific defect of hemostasis, the goal of treatment is to correct the defect. A typical example is the replacement of factor VIII by transfusion in patients with hemophilia. Specific treatment may be impossible, however, because bleeding may result from multiple defects or because no cause can be identified. In such situations, nontransfusional drugs that help to stop bleeding are indicated.<sup>1</sup> These drugs may also be indicated for patients who refuse blood transfusion or for those who undergo surgical procedures associated with large blood losses necessitating many transfusions of donated blood. Many nontransfusional hemostatic drugs have been evaluated, but only a few have proven clinical efficacy. This article will review antifibrinolytic amino acids (aminocaproic acid and tranexamic acid), aprotinin, desmopressin, and conjugated estrogens.

**ANTIFIBRINOLYTIC AMINO ACIDS**

Two synthetic derivatives of the amino acid lysine, 6-aminohexanoic acid (aminocaproic acid) and 4-(aminomethyl)cyclohexanecarboxylic acid (tranexamic acid), have antifibrinolytic activity in humans.<sup>2,3</sup> Both drugs bind reversibly to plasminogen and thereby block the binding of plasminogen to fibrin and its activation and transformation to plasmin (Fig. 1).<sup>4,5</sup> Aminocaproic acid and tranexamic acid (which is about 10 times more potent than aminocaproic acid and has a longer half-life) are effective even when bleeding is not associated with laboratory signs of excessive fibrinolysis.<sup>6</sup> Since both drugs enter the extravascular space and accumulate in tissues,<sup>7</sup> the basis for their efficacy is thought to be the inhibition of tissue fibrinolysis and the consequent stabilization of clots.

**Primary Menorrhagia**

Excessive menstrual bleeding is the most frequent cause of iron-deficiency anemia in women of reproductive age. Tranexamic acid reduces blood loss by

40 to 50 percent, as documented in a randomized controlled trial in 76 women.<sup>8</sup> The drug is thought to act by inhibiting plasminogen activator, which is present in high concentrations in the endometrium.<sup>8</sup> Its use is recommended only when the presence of organic lesions in the uterus has been ruled out and when combined estrogen-progestogen preparations, which control dysmenorrhea and menstrual irregularity more effectively, are unacceptable or contraindicated. The recommended oral dose of tranexamic acid is 10 to 15 mg per kilogram of body weight every eight hours, from the onset of menstrual bleeding until it is arrested.

**Gastrointestinal Bleeding**

The use of antifibrinolytic drugs in patients with gastrointestinal lesions that cause bleeding is rational, because the local concentration of fibrinolytic enzymes is high in the digestive tract.<sup>9</sup> Clinical trials of tranexamic acid in patients with upper gastrointestinal bleeding have had conflicting results.<sup>1,6</sup> A meta-analysis of results in 1267 patients with peptic ulcers, mucosal erosions, or other causes of bleeding found reductions of 20 to 30 percent in recurrent bleeding, 30 to 40 percent in the need for surgery, and 40 percent in mortality.<sup>10</sup> Despite these results, tranexamic acid is not widely used to treat patients with bleeding from the upper digestive tract because of the efficacy of other medical and endoscopic treatments.


**Bleeding in the Urinary Tract**

The urine and the urinary tract mucosa are very rich in plasminogen activators, which facilitate the lysis of clots.<sup>7</sup> After prostatectomy, urine dissolves clots in the prostatic cavity, resulting in hematuria and sometimes anemia. In clinical trials involving patients who had undergone prostatectomy, aminocaproic acid or tranexamic acid reduced blood loss by approximately 50 percent, as compared with placebo.<sup>11-13</sup> The recommended dosage of tranexamic acid is 10 to 15 mg per kilogram every eight hours intravenously, starting immediately after surgery, followed by 20 mg per kilogram orally every eight hours until macroscopic hematuria stops. The corresponding dosage of aminocaproic acid is 50 to 60 mg per kilogram intravenously six times per day, followed by the oral administration of the same dose. The drugs are not known to reduce the need for transfusion or to decrease mortality after prostatectomy, however, and they are therefore not given routinely. These drugs are contraindicated in patients with bleeding from the upper urinary tract because of the risk that clots will be retained in the ureter and the bladder.

**Oral Bleeding in Congenital and Acquired Coagulation Disorders**

Antifibrinolytic drugs are useful for the control of bleeding after dental extractions in patients with he-

From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Istituto di Ricovero e Cura a Carattere Scientifico Maggiore Hospital, and the University of Milan, Milan, Italy. Address reprint requests to Dr. Mannucci at Via Pace 9, 20122 Milan, Italy.  
©1998, Massachusetts Medical Society.



**Figure 1.** Antifibrinolytic Action of Aminocaproic Acid and Tranexamic Acid.

The upper diagram shows the activation of plasminogen on the fibrin surface. Plasminogen binds to fibrin at a lysine-binding site and is changed to plasmin, its activated form. Plasmin degrades fibrin into fibrin-degradation products. In the lower diagram, aminocaproic acid or tranexamic acid blocks the lysine-binding site on plasminogen, which is essential for binding to fibrin, and thereby prevents the activation of plasminogen on the surface of fibrin, although plasmin generation does occur.

mophilia, because the oral mucosa and saliva are rich in plasminogen activators.<sup>14</sup> In two small clinical trials, aminocaproic acid or tranexamic acid reduced recurrent bleeding and the amount of clotting-factor-replacement therapy needed.<sup>15,16</sup> In adults, the recommended oral dose is 50 to 60 mg of aminocaproic acid per kilogram every four hours or 20 to 25 mg of tranexamic acid per kilogram every eight hours until the dental sockets are completely healed. Mouthwashes containing tranexamic acid (1 g every six hours) are effective for the prevention of oral bleeding in patients with hemophilia<sup>17</sup> and in patients who require dental extraction while receiving long-term oral anticoagulant therapy.<sup>18</sup> Extraction can be performed without stopping or reducing the dose of the anticoagulant agent, which may increase the risk of thrombosis in patients with atrial fibrillation or artificial heart valves.<sup>18</sup>

#### Bleeding in Patients with Thrombocytopenia

In two uncontrolled studies of 30 patients with megakaryocytic or megakaryocytic thrombocytopenia, aminocaproic acid was effective in stopping mucosal bleeding (in the nose, uterus, or gastrointestinal tract) and bleeding associated with dental extraction, without affecting platelet counts.<sup>19,20</sup> Transfusion requirements may not be reduced by the use of these drugs, however.

#### Bleeding after Thrombolytic Treatment

Thrombolytic therapy in patients with acute myocardial infarction may be complicated by bleeding due to hyperfibrinolysis.<sup>21</sup> There is little evidence, however, that antifibrinolytic drugs (lysine derivatives and aprotinin, discussed below) are useful when bleeding complications develop during or shortly after thrombolytic treatment.

#### Reducing Blood Loss during Cardiac Surgery

Cardiac surgery is the prototypical operation in which the adoption of blood-saving measures is warranted. Factors contributing to the relatively large blood losses in cardiac surgery include the size of the surgical wound, the exposure of blood to artificial surfaces in the extracorporeal oxygenator, enzymatic and mechanical injury to platelets and coagulation factors, and hyperfibrinolysis during and after cardiopulmonary bypass. The results of clinical trials involving at least 1000 patients who were treated with tranexamic acid or aminocaproic acid have consistently demonstrated that either drug reduces blood loss by 30 to 40 percent, as compared with placebo.<sup>22-27</sup>

The following regimens were the most effective: for aminocaproic acid, a bolus intravenous dose of 150 mg per kilogram before the operation, followed by an infusion of 15 mg per kilogram per hour during the operation,<sup>24</sup> and for tranexamic acid, 10 mg

per kilogram given intravenously before the operation, followed by 1 mg per kilogram per hour during the operation.<sup>27</sup> In these studies, however, the amount of blood products given, the most important measure of the efficacy of prophylactic therapy, was either not measured or not reduced by antifibrinolytic drugs,<sup>22-27</sup> and none of the studies were of sufficient size to determine whether the incidence of serious side effects was increased by the treatment. Other nontransfusional hemostatic drugs, such as aprotinin and desmopressin, have also been used; they are discussed below.

**Joint Replacement**

In a randomized, controlled study of 86 patients undergoing knee replacement, the patients given a single dose of 10 mg of tranexamic acid per kilogram before the tourniquet was released lost less blood than those given placebo (mean blood loss, 730 vs. 1410 ml) and needed fewer transfusions.<sup>28</sup> These findings were confirmed by a similar study involving 76 patients.<sup>29</sup> Despite these results, antifibrinolytic drugs and hemostatic drugs in general cannot be recommended for routine prophylaxis during joint replacement, since the two to three units of blood needed by most patients can easily be supplied through a program of storing autologous blood for transfusion.<sup>30</sup> The use of drugs to reduce bleeding should therefore be considered only for patients in whom large blood losses are predicted, such as those undergoing double joint replacement or repeated operations.

**Orthotopic Liver Transplantation**

Patients undergoing orthotopic liver transplantation lose large amounts of blood, in part because of preexisting coagulopathy and intraoperative fibrinolysis. In a clinical study of 45 patients given high-dose tranexamic acid (20 to 30 mg per kilogram) or placebo during surgery, treated patients had about 50 percent less intraoperative blood loss and required fewer transfusions.<sup>31</sup> These preliminary results need confirmation.

The therapeutic indications for antifibrinolytic amino acids and the corresponding evidence of their efficacy are summarized in Table 1. Aminocaproic acid or tranexamic acid has been used in patients with other hemorrhagic conditions (such as epistaxis, bleeding after tonsillectomy, and secondary bleeding after traumatic hyphema), but the available data are insufficient to establish indications for the treatment of these conditions. The drugs are contraindicated in patients with subarachnoid bleeding, because they may induce vasospasm and ischemic stroke.<sup>32-34</sup>

**Side Effects**

The side effects of tranexamic acid and aminocaproic acid are dose-dependent and usually involve

**TABLE 1.** INDICATIONS FOR THE USE OF THE ANTIFIBRINOLYTIC DRUGS TRANEXAMIC ACID AND AMINOCAPROIC ACID IN THE TREATMENT OF EXCESSIVE BLEEDING.

| CLINICAL SITUATION                                       | STUDY   | GRADE OF EVIDENCE* |
|--|---|--------------------|
| Primary menorrhagia                                      | Bonnar and Sheppard <sup>8</sup>  | A                  |
| Upper gastrointestinal bleeding                          | Henry and O'Connell <sup>10</sup>   | A                  |
| Dental extraction in patients with coagulation disorders | Walsh et al. <sup>15</sup><br>Forbes et al. <sup>16</sup><br>Sindet-Pedersen et al. <sup>18</sup> | A                  |
| Bleeding associated with thrombocytopenia                | Gardner and Helmer <sup>19</sup><br>Bartholomew et al. <sup>20</sup>                              | B                  |


\*The evidence has been graded as A, B, or C as follows: A denotes that the therapeutic value of tranexamic acid or aminocaproic acid has been demonstrated by clinical trials evaluating its safety and efficacy, B that safety and efficacy have been demonstrated by well-conducted studies but no clinical trials, and C that safety and efficacy have been demonstrated by case studies or reports but no well-conducted studies.

the gastrointestinal tract (nausea, vomiting, abdominal pain, and diarrhea). The main risk entailed by these drugs is that thrombotic complications will result from the inhibition of fibrinolysis, which is a natural mechanism of defense against the formation of thrombus. There are at least 10 case reports describing the formation of thrombi in association with the use of these drugs. On the other hand, no striking increase in the risk of thrombosis has been observed when the drugs have been used during operations that are often complicated by venous and arterial thromboembolism, such as cardiac surgery<sup>22-26</sup> and knee replacement.<sup>28,29</sup> However, these studies were not designed to evaluate thrombotic complications, and most were too small to detect differences in outcomes with relatively low incidence, such as stroke, myocardial infarction, and coronary-bypass graft occlusion.

**APROTININ**

Aprotinin, a polypeptide with a molecular weight of 6512, is extracted from bovine lung. It inhibits the action of several serine proteases (such as trypsin, chymotrypsin, plasmin, and tissue and plasma kallikrein) through the formation of reversible enzyme-inhibitor complexes.<sup>35,36</sup> By inhibiting kallikrein, aprotinin indirectly inhibits the formation of activated factor XII, a biochemical reaction normally amplified by kallikrein by means of a positive-feedback mechanism<sup>37</sup> (Fig. 2). Hence, aprotinin inhibits the initiation of both coagulation and fibrinolysis induced by the contact of blood with a foreign surface. Aprotinin does not affect platelet function.<sup>38-40</sup>

Aprotinin is inactive when given orally. It is administered intravenously in an initial loading dose, followed by a continuous infusion. The enzymatic



**Figure 2.** Inhibition of the Contact System and of Fibrinolysis by Aprotinin.

The arrows indicate activation or release. The broken lines indicate inhibition. Activation of the contact system is initiated by the binding of plasma factor XII to a negatively charged surface, where autoactivation of factor XII occurs, converting it to activated factor XII. The presence of small amounts of activated factor XII converts prekallikrein to kallikrein, which in turn activates factor XII, cleaves high-molecular-weight kininogen, generating the vasoactive peptide bradykinin, and converts prourokinase to urokinase. Fibrinolysis consists of the activation of plasminogen, which is converted to the enzyme plasmin, which in turn digests fibrin, generating fibrin-degradation products. Plasminogen is activated by urokinase and by tissue plasminogen activator. Aprotinin acts as an inhibitor of kallikrein and plasmin.

activity of the compound is expressed in kallikrein inactivation units (KIU). Plasma concentrations of 125 KIU per milliliter are necessary to inhibit plasmin, and concentrations of 300 to 500 KIU per milliliter are needed to inhibit kallikrein.<sup>36</sup>

#### Cardiac Surgery

The broad antiproteolytic action of aprotinin prompted its use in reducing blood loss in patients undergoing cardiac surgery, during which there is increased plasma proteolysis. In an open-label, randomized study of 22 patients undergoing repeated cardiac surgery, blood loss in the patients who were treated with aprotinin (2 million KIU before surgery and a continuous infusion of 0.5 million KIU during surgery) was 80 percent less and transfusion requirements were 60 percent lower than in the control group.<sup>41</sup> Subsequently, double-blind studies involving more than 500 patients demonstrated the effectiveness of aprotinin in patients undergoing common operations such as valve replacement and coronary-artery bypass grafting.<sup>42-47</sup> It is also effective in operations characterized by particularly large blood

losses, such as those in patients taking aspirin,<sup>48</sup> in patients with endocarditis,<sup>49</sup> and in patients undergoing heart transplantation.<sup>50</sup>

Lower-dose regimens have subsequently been proposed — for example, 3 million to 4 million KIU, or 2 million KIU added to the oxygenator.<sup>51-53</sup> The regimen of 3 million to 4 million KIU of aprotinin is as effective hemostatically as the full-dose aprotinin regimen, but the oxygenator-only regimen may not be.<sup>51</sup> Aprotinin is less effective when given postoperatively than when given prophylactically.<sup>54</sup> The criteria for choosing between aprotinin and other hemostatic drugs for patients undergoing cardiac surgery are discussed below.

#### Orthotopic Liver Transplantation

A relatively low dose of aprotinin (2 million KIU) resulted in a reduction of approximately 35 percent in blood loss and a 50 percent reduction in transfusion requirements, as compared with no treatment, in a total of 20 patients undergoing orthotopic liver transplantation.<sup>55</sup> In a subsequent study of a larger dose (2 million KIU after the induction of anesthe-

sia, followed by an infusion of 0.5 million KIU per hour during the operation) in a total of 24 patients, transfusion requirements in the treated patients were less than a third of those in the control patients.<sup>56</sup> These studies were neither randomized nor controlled. In one small, randomized study of a total of 20 patients, aprotinin was not more effective than placebo.<sup>57</sup>

#### Side Effects

Aprotinin is a heterologous polypeptide, and therefore it can cause hypersensitivity reactions, particularly after repeated exposure. In one study of 240 patients given aprotinin two or more times, 7 had hypersensitivity reactions (ranging from skin flushing to severe circulatory depression). Most reactions occurred when aprotinin was administered a second time within six months after the first exposure and were not severe.<sup>58</sup>

Aprotinin can cause venous and arterial thrombosis and thus the occlusion of coronary-bypass grafts and other vascular grafts. In controlled studies with coronary angiography, however, aprotinin did not lead to an increased rate of early occlusion of saphenous-vein or internal-mammary-artery grafts.<sup>47,59-61</sup> Similarly, in a small study, there was no increased risk of venous thromboembolism after hip replacement in patients treated with aprotinin.<sup>62</sup> In prospective, placebo-controlled, randomized studies of aprotinin-treated patients who had undergone coronary-artery bypass surgery, there was no increase in the occurrence of myocardial infarction or death.<sup>51</sup> Pooled analysis of data from six studies of coronary-artery bypass surgery, which evaluated a total of 861 patients assigned to receive aprotinin or placebo,<sup>63</sup> found a lower prevalence of stroke among the patients treated with aprotinin.

Recently, concern that aprotinin, which is extracted from bovine lungs, might transmit the agent responsible for bovine spongiform encephalopathy and new-variant Creutzfeldt-Jakob disease has led to the withdrawal of the drug in Italy. No other country, in Europe or elsewhere, has taken this step so far. The manufacturers of aprotinin state that the bovine lungs used to extract aprotinin have been collected in geographic areas in which no cases of transmissible spongiform encephalopathy have been recorded, and there is no evidence that any patients with the disorder have received aprotinin.

#### DESMOPRESSIN

Plasma concentrations of factor VIII, the clotting factor that is deficient or defective in patients with hemophilia A, and von Willebrand factor, the adhesive protein that is deficient or defective in patients with von Willebrand's disease, can be increased for a short time by the administration of 1-deamino-8-D-arginine vasopressin (desmopressin), an analogue of

arginine vasopressin.<sup>64</sup> These effects, which mimic replacement therapy with blood products, form the rationale for the use of desmopressin in the treatment of patients with hemophilia A or von Willebrand's disease, both of which are congenital bleeding disorders.<sup>65-67</sup> The evidence of efficacy is so clear that no controlled clinical trials have been judged necessary.

Desmopressin has also been used in patients with other congenital and acquired bleeding disorders.<sup>66,68,69</sup> In such patients, the effect of desmopressin may be mediated by the attainment of supranormal plasma concentrations of von Willebrand factor and the appearance of ultralarge multimers of this factor,<sup>70</sup> which support platelet adhesion to the vascular subendothelium more actively than multimers of normal size.<sup>71</sup> Increased hemostasis may also be mediated by high plasma concentrations of factor VIII, a rate-accelerating factor in the process of fibrin formation.<sup>72</sup>

#### Congenital Bleeding Disorders

The optimal intravenous or subcutaneous dose of desmopressin in patients with congenital bleeding disorders is 0.3  $\mu\text{g}$  per kilogram, and the optimal intranasal dose is 300  $\mu\text{g}$  in adults and 150  $\mu\text{g}$  in children.<sup>73,74</sup> Plasma concentrations of factor VIII and von Willebrand factor are approximately doubled or quadrupled by the administration of desmopressin, reaching a peak 30 to 60 minutes after intravenous infusion and 60 to 90 minutes after subcutaneous or intranasal administration.<sup>73,74</sup> These doses can be repeated as clinically necessary at intervals of 12 to 24 hours, but tachyphylaxis may occur after three or four doses.<sup>75</sup>

Most patients with low plasma concentrations of normal von Willebrand factor (that is, those with type I von Willebrand's disease) respond to desmopressin with increases in factor VIII concentrations that are similar to or even greater than those in patients with mild hemophilia,<sup>75</sup> and their bleeding time becomes normal.<sup>70,75</sup> However, the bleeding time in patients with severe von Willebrand factor deficiency (type III von Willebrand's disease)<sup>76</sup> or those with dysfunctional von Willebrand factor (type II disease)<sup>70</sup> is usually not shortened.

Desmopressin is the treatment of choice for patients with mild hemophilia A or type I von Willebrand's disease who have spontaneous bleeding or who are scheduled to undergo surgery. It shortens or normalizes the bleeding time in some patients with congenital defects of platelet function.<sup>77</sup> Although the effect of desmopressin on a laboratory measure such as the bleeding time may not correspond to a hemostatic effect in patients, the results in a few well-studied cases suggest that desmopressin may be an alternative to blood products during or after surgery or childbirth in such patients.<sup>78</sup>

### Acquired Bleeding Disorders

Desmopressin has also been used in patients with uremia, who have complex abnormalities of hemostasis, reflected in part by a prolonged bleeding time.<sup>79</sup> In a group of these patients who were given an intravenous infusion of desmopressin, the prolonged bleeding time became normal for four to six hours in about 75 percent.<sup>68</sup> Desmopressin given before invasive procedures (such as biopsies and major surgery) seems to prevent bleeding,<sup>68</sup> but controlled studies of this effect are lacking. Currently, the clinical use of desmopressin in patients with uremia is based on the link between the degree of prolongation of the bleeding time and the patient's tendency toward excessive bleeding.<sup>79</sup> Conjugated estrogens are an alternative to desmopressin for patients with uremia who have bleeding problems.

### Cirrhosis

In spite of the fact that patients with cirrhosis have high plasma concentrations of factor VIII and von Willebrand factor, they have prolonged bleeding times that are shortened by intravenous desmopressin.<sup>69,80</sup> Hence, the drug might be used as a prophylactic treatment for patients who need invasive diagnostic procedures and have a prolonged bleeding time. It is not effective, however, in controlling acute gastrointestinal bleeding in patients with cirrhosis.<sup>81</sup>

### Reducing Blood Loss during Surgery

In a single study of 70 patients undergoing complex cardiac surgery, desmopressin given at the time of chest closure reduced blood loss and transfusion requirements by about 30 percent.<sup>82</sup> In three studies of a total of 330 patients who were undergoing simpler cardiac operations, however, there were no significant differences between desmopressin and placebo.<sup>83-85</sup> In a meta-analysis of 17 clinical trials, which included a total of 1171 patients, desmopressin significantly reduced postoperative blood loss (by 9 percent, a value of little clinical importance).<sup>86</sup> Perhaps the low efficacy of desmopressin in cardiac surgery is due to its fibrinolytic activity,<sup>64</sup> an unfavorable property in treating a condition accompanied by hyperfibrinolysis. The main therapeutic indications for the use of desmopressin and the corresponding evidence are summarized in Table 2.

### Side Effects

Common side effects include mild facial flushing and headache. Because of its potent antidiuretic effect, desmopressin can cause water retention and hyponatremia.<sup>87</sup> In patients given more than one dose, plasma sodium and body weight should be measured daily and excessive administration of fluids avoided. Arterial thrombosis (sometimes causing fatal stroke or myocardial infarction) has occurred in

**TABLE 2.** INDICATIONS FOR THE USE OF DESMOPRESSIN IN THE TREATMENT OF EXCESSIVE BLEEDING.

| CLINICAL SITUATION                                   | STUDY   | GRADE OF EVIDENCE* |
|--|---|--------------------|
| Mild hemophilia A or type I von Willebrand's disease | Mannucci et al. <sup>65</sup><br>Kobrinisky et al. <sup>66</sup><br>de la Fuente et al. <sup>67</sup> | B                  |
| Congenital defects of platelet function              | Rao et al. <sup>77</sup><br>DiMichele and Hathaway <sup>78</sup>                                      | C                  |
| Uremia   | Mannucci et al. <sup>68</sup>   | C                  |
| Cirrhosis  | Mannucci et al. <sup>69</sup><br>Burroughs et al. <sup>80</sup>                                       | C                  |
| Drug-induced bleeding (aspirin, ticlopidine)         | Kobrinisky et al. <sup>66</sup><br>Mannucci et al. <sup>69</sup>                                      | C                  |

\*The evidence has been graded as A, B, or C as follows: A denotes that the therapeutic value of desmopressin has been demonstrated by clinical trials evaluating its safety and efficacy, B that safety and efficacy have been demonstrated by well-conducted studies but no clinical trials, and C that safety and efficacy have been demonstrated by case studies or reports but no well-conducted studies.

a few patients treated with desmopressin.<sup>88</sup> In patients at high risk for thrombosis (such as those undergoing coronary-artery bypass grafting), there was no excess rate of thrombotic complications among those given desmopressin.<sup>89</sup>

### HEMOSTATIC DRUGS AS PROPHYLAXIS IN PATIENTS UNDERGOING CARDIAC SURGERY

Aminocaproic acid, tranexamic acid, desmopressin, and aprotinin have all been evaluated in patients undergoing cardiac surgery. On the basis of direct comparisons<sup>90-92</sup> and a meta-analysis,<sup>93</sup> all four agents reduce operative blood loss. Aprotinin is most effective in reducing blood loss, followed in descending order by tranexamic acid, aminocaproic acid, and desmopressin<sup>93</sup>; their order with respect to cost at the most commonly recommended dose is the same. In terms of reducing blood-transfusion requirements, the most important criterion for efficacy, the results also favor aprotinin. In terms of safety, firm data from clinical trials demonstrating that the frequency of graft occlusion does not increase with use of the drug are available only for aprotinin.

The cumulative evidence leads to the choice of aprotinin, but it should be reserved for patients who are likely to need transfusion of donated blood, notably those undergoing second operations, those who have preexisting hemostatic defects or are taking antiplatelet drugs, and those with sepsis; preoperative testing of hemostasis is not useful. The prophylactic use of aprotinin in all patients is not recommended, because many cardiac surgical procedures are not usually associated with the need for donated blood and because hypersensitivity reactions can occur on second exposure to the drug.

**TABLE 3.** NONTRANSFUSIONAL TREATMENT OF BLEEDING IN PATIENTS WITH UREMIA.

| COMPOUND             | ONSET OF EFFECT | DURATION OF EFFECT | INDICATIONS*   |
|----------------------|-----------------|--------------------|--|
| Desmopressin         | Immediate       | 6–8 hr             | Acute bleeding<br>Before biopsy or emergency surgery   |
| Conjugated estrogens | Delayed         | 10–15 days         | Chronic, recurrent bleeding<br>Before elective surgery |
| Erythropoietin       | Delayed         | Sustained          | Prevention of bleeding                                 |

\*The safety and efficacy of the drugs in question for all indications are supported by case studies or reports but no well-conducted studies (grade C).<sup>68,94,95,97</sup>

### CONJUGATED ESTROGENS

Conjugated estrogens shorten prolonged bleeding times and reduce or stop bleeding in patients with uremia.<sup>94,95</sup> The mechanism of conjugated estrogens' effect on the bleeding time in these patients is unknown, nor is it known whether other estrogen preparations have this effect. Conjugated estrogens can be given intravenously or orally. In patients with uremia, a single daily infusion of 0.6 mg per kilogram, repeated for four to five days, shortened the bleeding time by approximately 50 percent for at least two weeks.<sup>95</sup> A daily oral dose of 50 mg shortened the bleeding time after an average of seven days of treatment.<sup>96</sup>

The clinical use of conjugated estrogens in patients with uremia (like the use of desmopressin) is based on data indicating that the tendency of these patients to have bleeding is directly related to the degree of prolongation of the bleeding time.<sup>79</sup> The chief advantage of conjugated estrogens over desmopressin is the longer duration of their effect on the bleeding time (10 to 15 days, as compared with 6 to 8 hours). Hence, conjugated estrogens should be given when long-lasting hemostasis is required — for example, to prevent bleeding during elective surgical procedures or to treat recurrent episodes of gastrointestinal or nasal bleeding (Table 3). On the other hand, desmopressin should be given when an immediate effect on hemostasis is required — for instance, to stop acute bleeding or to prevent bleeding at the time of emergency surgery. The two products can be given concurrently, thus exploiting the different timing of their maximal effects.

In patients with chronic renal insufficiency, recombinant erythropoietin causes a dose-dependent increase in the hematocrit and eliminates the need for blood transfusions.<sup>98</sup> The progressive increases in the hematocrit are paralleled by a pronounced shortening of the bleeding time and the improvement of platelet adhesion.<sup>97</sup> Because most patients with chronic renal insufficiency are now regularly treated with erythropoietin, short-acting hemostatic drugs such as desmopressin and conjugated estrogens are rec-

ommended only for patients with acute or subacute renal failure.

Conjugated estrogens are well tolerated, and side effects are negligible or absent. Since no more than five to seven daily doses are recommended, adverse effects due to estrogenic hormonal activity are usually avoided.

### CONCLUSIONS

The antifibrinolytic drugs aminocaproic acid and tranexamic acid are useful in patients with a broad range of hemorrhagic conditions, particularly when there is excessive bleeding from mucosal sites. Desmopressin is the treatment of choice for patients with mild hemophilia or type I von Willebrand's disease. It has also been used successfully to treat or prevent bleeding in patients with other hemorrhagic disorders, including congenital defects of platelet function, chronic liver disease, and hemostatic defects induced by the therapeutic use of antithrombotic drugs such as aspirin and ticlopidine.<sup>66,69</sup> There have been no well-conducted clinical trials demonstrating the efficacy of desmopressin.

In cardiac surgery, antifibrinolytic drugs (lysine derivatives and aprotinin) are more effective than desmopressin; aprotinin is preferred because its efficacy and safety have been more extensively evaluated. However, aprotinin should be used prophylactically only when the patient is expected to need transfusions of donated blood or when the patient refuses transfusion for religious or other reasons.

Hemostatic agents for topical use, the so-called fibrin tissue adhesives, have not been considered in this review, because objective data on their efficacy and safety are limited.<sup>99</sup> Much effort will undoubtedly be directed toward developing and evaluating newer topical agents. In addition, efforts are being made to replace plasma-derived coagulation factors with the corresponding recombinant products. Recombinant factor VIII, factor IX, and activated factor VII are already licensed (the last only in Europe); clinical studies of recombinant von Willebrand factor will soon begin.

## REFERENCES

1. Verstraete M. Haemostatic drugs. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. *Haemostasis and thrombosis*. 3rd ed. Vol. 2. Edinburgh, Scotland: Churchill Livingstone, 1994:1057-73.
2. Okamoto S, Nakajima T, Okamoto U, et al. A suppressing effect of  $\epsilon$ -amino-n-caproic acid on the bleeding of dogs, produced with the activation of plasmin in the circulatory blood. *Keio J Med* 1959;8:247-66.
3. Andersson L, Nilsson IM, Nilehn JE, Hedner U, Granstrand B, Melander B. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. *Scand J Haematol* 1965;2:230-47.
4. Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation: influence of omega-aminocarboxylic acids. *Biochim Biophys Acta* 1975;393:55-65.
5. Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. *Biochim Biophys Acta* 1981;673:75-85.
6. Verstraete M. Clinical application of inhibitors of fibrinolysis. *Drugs* 1985;29:236-61.
7. Andersson L, Nilsson IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. *Ann NY Acad Sci* 1968;146:642-58.
8. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. *BMJ* 1996;313:579-82.
9. Cox HT, Poller L, Thomson JM. Evidence for the release of gastric fibrinolytic activity into peripheral blood. *Gut* 1969;10:404-7.
10. Henry DA, O'Connell DL. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. *BMJ* 1989;298:1142-6.
11. Gamba G, Fornasari PM, Grignani G, Dolci D, Colloï D. Haemostasis during transvesical prostatic adenectomy: a controlled trial on the effects of drugs with antifibrinolytic and thrombin-like activities. *Blut* 1979;39:89-98.
12. Miller RA, May MW, Hendry WF, Whitfield HN, Wickham JE. The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy. *Br J Urol* 1980;52:26-8.
13. Stefanini M, English HA, Taylor AE. Safe and effective, prolonged administration of epsilon aminocaproic acid in bleeding from the urinary tract. *J Urol* 1990;143:559-61.
14. Sindet-Pedersen S. Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. *J Clin Pharmacol* 1987;27:1005-8.
15. Walsh PN, Rizza CR, Matthews JM, et al. Epsilon-aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. *Br J Haematol* 1971;20:463-75.
16. Forbes CD, Barr RD, Reid G, et al. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. *BMJ* 1972;2:311-3.
17. Sindet-Pedersen S, Stenbjerg S. Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery. *J Oral Maxillofac Surg* 1986;44:703-7.
18. Sindet-Pedersen S, Ramström G, Bernvil S, Blombäck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. *N Engl J Med* 1989;320:840-3.
19. Gardner FH, Helmer RE III. Aminocaproic acid: use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. *JAMA* 1980;243:35-7.
20. Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. *Arch Intern Med* 1989;149:1959-61.
21. Collier BS. Platelets and thrombolytic therapy. *N Engl J Med* 1990;322:33-42.
22. DelRossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R. Prophylactic treatment of postperfusion bleeding using EACA. *Chest* 1989;96:27-30.
23. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prospective, double-blind study. *J Thorac Cardiovasc Surg* 1994;108:99-106.
24. Vander Salm TJ, Kaur S, Lancey RA, et al. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. *J Thorac Cardiovasc Surg* 1996;112:1098-107.
25. Karski JM, Teasdale SJ, Norman P, et al. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid: double-blind, randomized clinical trial. *J Thorac Cardiovasc Surg* 1995;110:835-42.
26. Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R. Tranexamic acid reduces postbypass blood use: a double blinded, prospective, randomized study of 210 patients. *Ann Thorac Surg* 1996;61:1131-5.
27. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. *Anesthesiology* 1995;82:383-92.
28. Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double blind study of 86 patients. *J Bone Joint Surg Br* 1996;78:434-40.
29. Hiippala ST, Strid LJ, Wennerstrand MI, et al. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. *Anesth Analg* 1997;84:839-44.
30. Kurdy NM. Transfusion needs in hip and knee arthroplasty. *Ann Chir Gynaecol* 1996;85:86-9.
31. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. *Anesthesiology* 1996;85:1043-8.
32. Tovi D, Nilsson IM, Thulin CA. Fibrinolysis and subarachnoid haemorrhage: inhibitory effect of tranexamic acid: a clinical study. *Acta Neurol Scand* 1972;48:393-402.
33. Vermeulen M, Lindsay KW, Murray GD, et al. Antifibrinolytic treatment in subarachnoid hemorrhage. *N Engl J Med* 1984;311:432-7.
34. Adams HP Jr, Kassell NF, Torner JC, Haley EC Jr. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy: a report of the Cooperative Aneurysm Study. *Neurology* 1987;37:1586-91.
35. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. *Arzneimittelforschung* 1983;33:479-94.
36. Hoffmann H, Siebeck M, Thetter O, Jochum M, Fritz H. Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. In: Abe K, Moriya H, Fujii S, eds. *Kinins V. Part B. Vol. 247B of Advances in experimental medicine and biology*. New York: Plenum Press, 1989:35-42.
37. Kluff C. Pathomechanisms of defective hemostasis during and after extracorporeal circulation: contact phase activation. In: Friedel N, Hetzer R, Royston D, eds. *Blood use in cardiac surgery*. New York: Springer-Verlag, 1991:10-5.
38. van Oeveren W, Eijssman L, Roozendaal KJ, Wildevuur CR. Platelet preservation by aprotinin during cardiopulmonary bypass. *Lancet* 1988;1:644.
39. Orchard MA, Goodchild CS, Prentice CRM, et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. *Br J Haematol* 1993;85:533-41.
40. Wahba A, Black G, Koksche M, et al. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. *Thromb Haemost* 1996;75:844-8.
41. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. *Lancet* 1987;2:1289-91.
42. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasyolol). *J Thorac Cardiovasc Surg* 1989;97:364-72.
43. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin — preliminary results. *Thorac Cardiovasc Surg* 1989;37:89-91.
44. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. *Anesthesiology* 1990;73:1119-26.
45. Harder MP, Eijssman L, Roozendaal KJ, van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. *Ann Thorac Surg* 1991;51:936-41.
46. Cosgrove DM III, Heric B, Lytle BV, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. *Ann Thorac Surg* 1992;54:1031-6.
47. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study. *J Thorac Cardiovasc Surg* 1994;107:543-51.
48. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Aprotinin (Trasyolol) reduces bleeding after open heart surgery in patients taking aspirin and those with renal failure. *Anesthesiology* 1989;71:Suppl:A6. abstract.
49. Wildevuur CR, Eijssman L, Roozendaal KJ, Harder MP, Chang M, van Oeveren W. Platelet preservation during cardiopulmonary bypass with aprotinin. *Eur J Cardiothorac Surg* 1989;3:533-7.
50. Prendergast TW, Furukawa S, Beyer AJ III, Eisen HJ, McClurken JB, Jeevanandam V. Defining the role of aprotinin in heart transplantation. *Ann Thorac Surg* 1996;62:670-4.
51. Levy JH, Pifarre R, Schaff HV, et al. A multicenter double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the require-

- ment for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. *Circulation* 1995;92:2236-44.
52. Lemmer JH Jr, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. *Ann Thorac Surg* 1996;62:1659-67.
  53. Kawasuji M, Ueyama K, Sakakibara N, et al. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. *Ann Thorac Surg* 1993;55:1205-9.
  54. Cicek S, Demirkilic U, Ozal E, et al. Postoperative use of aprotinin in cardiac operations: an alternative to its prophylactic use. *J Thorac Cardiovasc Surg* 1996;112:1462-7.
  55. Neuhaus P, Bechstein WO, Lefebvre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. *Lancet* 1989;2:924-5.
  56. Mallet SV, Cox D, Burroughs AK, Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. *Lancet* 1990;336:886-7.
  57. Groh J, Welte M, Azad SC, Forst H, Pratschke T, Kratzer MA. Does aprotinin affect blood loss in liver transplantation? *Lancet* 1992;340:173.
  58. Dietrich W, Späth P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. *J Thorac Cardiovasc Surg* 1997;113:194-201.
  59. Havel M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. *J Thorac Cardiovasc Surg* 1994;107:807-10.
  60. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. *Eur J Cardiothorac Surg* 1994;8:651-6.
  61. Lass M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy. *Eur J Cardiothorac Surg* 1995;9:206-10.
  62. Hayes A, Murphy DB, McCarroll M. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. *J Clin Anesth* 1996;8:357-60.
  63. Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen. *Ann Thorac Surg* 1996;62:1575-7.
  64. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. *Br J Haematol* 1975;30:81-93.
  65. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's diseases. *Lancet* 1977;1:869-72.
  66. Kobrinsky NL, Israels ED, Gerrard JM, et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. *Lancet* 1984;1:1145-8.
  67. de la Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. *Ann Intern Med* 1985;103:6-14.
  68. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. *N Engl J Med* 1983;308:8-12.
  69. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. *Blood* 1986;67:1148-53.
  70. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. *Blood* 1982;59:1272-8.
  71. Sakariassen KS, Cattaneo M, van der Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. *Blood* 1984;64:229-36.
  72. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. *Br J Haematol* 1981;47:283-93.
  73. Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. *Thromb Haemost* 1987;58:1033-6.
  74. Kohler M, Hellstern P, Miyashita C, von Blohn G, Wenzel E. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). *Thromb Haemost* 1986;55:108-11.
  75. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). *Br J Haematol* 1992;82:87-93.
  76. Mannucci PM, Pareti FI, Holmberg L, Nilsson IM, Ruggeri ZM. Studies on the prolonged bleeding time in von Willebrand's disease. *J Lab Clin Med* 1976;88:662-71.
  77. Rao AK, Ghosh S, Sun L, et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects: a double-blind placebo-controlled trial. *Thromb Haemost* 1995;74:1071-8.
  78. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. *Am J Hematol* 1990;33:39-45.
  79. Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. *Am J Hematol* 1979;7:107-17.
  80. Burroughs AK, Matthews K, Qadiri M, et al. Desmopressin and bleeding time in patients with cirrhosis. *BMJ* 1985;291:1377-81.
  81. de Franchis R, Arcidiacono PG, Carpinelli L, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. *Hepatology* 1993;18:1102-7.
  82. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial. *N Engl J Med* 1986;314:1402-6.
  83. Rocha E, Llorens R, Paramo JA, Arcas R, Cuesta B, Trenor AM. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? *Circulation* 1988;77:1319-23.
  84. Hackmann T, Gascoyne RD, Naiman SC, et al. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. *N Engl J Med* 1989;321:1437-43.
  85. Ansell J, Klassen V, Lew R, et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. *J Thorac Cardiovasc Surg* 1992;104:117-23.
  86. Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery — a meta-analysis of double-blind, placebo-controlled trials. *Thromb Haemost* 1995;74:1064-70.
  87. Shepherd LL, Hutchinson RJ, Worden EK, Koopman CF, Coran A. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. *J Pediatr* 1989;114:470-2.
  88. Desmopressin and arterial thrombosis. *Lancet* 1989;1:938-9.
  89. Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. *Thromb Haemost* 1994;71:154-5.
  90. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. *Circulation* 1994;90:921-7.
  91. Blauhut B, Harringer W, Bettelheim P, Doran JE, Späth P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 1994;108:1083-91.
  92. Menichetti A, Tritapepe L, Ruvoletto G, et al. Changes in coagulation pattern, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. *J Cardiovasc Surg (Torino)* 1996;37:401-7.
  93. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. *Ann Thorac Surg* 1994;58:1580-8.
  94. Liu YK, Kosfeld RE, Marcum SG. Treatment of uraemic bleeding with conjugated oestrogen. *Lancet* 1984;2:887-90.
  95. Livio M, Mannucci PM, Viganò G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. *N Engl J Med* 1986;315:731-5.
  96. Shemin D, Elnour M, Amarantes B, Abuelo JG, Chazan JA. Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure. *Am J Med* 1990;89:436-40.
  97. Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. *Lancet* 1987;2:1227-9.
  98. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. *Lancet* 1986;2:1175-8.
  99. Martinowitz U, Sponitz WD. Fibrin tissue adhesives. *Thromb Haemost* 1997;78:661-6.